The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.
This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.
Andrew J. Cutler, MD,1,2 Christoph U. Correll, MD,3-7 Rakesh Jain, MD, MPH,8 Craig Chepke, MD,9,10 Hara E. Oyedeji, DNP, PMHNP-BC,11 Alejandro G. Hughes, MPH,12 Noah S. Webb, PhD,12 Michael J. Doane, PhD,13 Hemangi R. Panchmatia, MSc13
1Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY, USA; 2Neuroscience Education Institute, Lakewood Ranch, FL, USA; 3Department of Psychiatry, Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, USA; 4Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA; 5Center for Psychiatric Neuroscience, The Feinstein Institute for Medical Research, Northwell Health, New Hyde Park, NY, USA; 6Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin Berlin, Berlin, Germany; 7German Center for Mental Health (DZPG), partner site Berlin, Berlin, Germany; 8Texas Tech University School of Medicine-Permian Basin, Midland, TX, USA; 9Excel Psychiatric Associates, P.A., Huntersville, NC, USA; 10Atrium Health, Charlotte, NC, USA; 11Fortitude Behavioral Health, Baltimore, MD, USA; 12Optum, Inc., Eden Prairie, MN, USA; 13Alkermes, Inc., Waltham, MA, USA
